ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MDCX / news
CVKD (34) RDHL (52) NRSN (35) GRI (34) ⌘ Pro Terminal →

Why MDCX Stock surged +2.66% Today — RQD Quant Desk Flash

$1.93 +2.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.94

Medicus Pharma Ltd. (MDCX) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $3.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MDCX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MDCX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Medicus Pharma Ltd. (NASDAQ: MDCX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.93 (+2.66% 1D, market cap $3.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MDCX ranks #659 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MDCX compare to CVKD and RDHL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MDCX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CVKD (Cadrenal Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M) and RDHL (Redhill Biopharma Ltd.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $3.4M). Among the 5-stock peer group, MDCX leads on earnings multiple (N/A) while MDCX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MDCX?
▼

Per MDCX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001997296), Medicus Pharma Ltd. generated $96.2M in revenue (+207.3% YoY), -$47.3M in net income, and -$22.8M in free cash flow against $10.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.94 (+0.29%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (7)Whales (3)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.9% Base Target
$134 Bull$2 Base$1 Bear
📬 FREE MDCX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MDCX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY MDCX SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 20.5 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$3.28-17.1% Next Q
Q2 (-2Q)
39
Grade E$2.72-9.9% Next Q
Q3 (-1Q)
37
Grade E$2.45-21.2% Next Q
Current
34
Grade E$1.93-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MDCX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MDCX currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.82) and Max Pain ($2.03) forces dealer call-delta covering toward $133.88.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MDCX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MDCX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why MDCX Stock surged +2.66% Today — RQD Quant Desk Flash

Medicus Pharma Ltd. (MDCX) surged +2.66% to $1.93, trading at 2% of its 52-week range ($1.82 – $127.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($1.82 – $127.5) with RSI-14 at 20.5 (OVERSOLD (<32)).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.93 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live MDCX Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MDCX)

  • ✓Walkthrough of MDCX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MDCX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -86.50%🛡️ HOLDING TREND SUPPORT
2026-11-03O $2.15H $2.15L $1.88C $1.93VOL 86.7K
RES: $7.00SUP: $1.62SMA50: $6.82SMA200: $22.17
$88.56$65.05$41.54$18.03$-5.48RES $7.00SUP $1.62$1.932026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MDCX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MDCX Butterfly Map → + Track MDCX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +207.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MDCX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MDCX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MDCX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MDCX)

Health Care Rank #659 of 1015 ⚔️ CVKD vs MDCX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MDCX vs. CVKD, RDHL, NRSN, GRI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Medicus Pharma Ltd. (MDCX) ranks #659 by composite RQD confidence (34/100, grade E) and #964 by equity capitalization ($3.6M). Within this direct 5-issuer industry benchmark cohort, MDCX leads on earnings valuation at N/A trailing P/E, while MDCX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RDHL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with MDCX at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MDCX ACTIVE
Medicus Pharma Ltd.
E 34/100 — — -35.0% +2.66% $3.6M Benchmark Subject
CVKD
Cadrenal Therapeutics Inc.
E 34/100 — — -35.0% +5.58% $3.5M /cvkd-vs-mdcx →
RDHL
Redhill Biopharma Ltd.
D+ 52/100 — — — +13.87% $3.4M /rdhl-vs-mdcx →
NRSN
NeuroSense Therapeutics Ltd.
D- 35/100 — — -35.0% -28.14% $3.8M /nrsn-vs-mdcx →
GRI
GRI Bio Inc.
E 34/100 — — -35.0% -4.57% $3.3M /gri-vs-mdcx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001997296 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Medicus Pharma Ltd. (MDCX) reported GAAP revenue of $96.2M (+207.3% vs. FY2024 revenue of $31.3M , and +626.4% cumulative change since FY2023) , GAAP net income of -$47.3M, operating cash flow of -$22.8M, and free cash flow of -$22.8M (-122.3% YoY). On the balance sheet, MDCX closed FY2025 with $10.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $96.2M -$47.3M -$22.8M -$22.8M $10.1M —
FY2024 (FY) 2024-12-31 $31.3M -$11.2M -$10.2M -$10.2M $5.6M —
FY2023 (FY) 2023-12-31 $13.2M -$5.3M -$4.2M -$4.2M — —

3. MDCX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MDCX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Medicus Pharma Ltd. (NASDAQ: MDCX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.93 (+2.66% 1D, market cap $3.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MDCX ranks #659 in composite RQD confidence.

How does MDCX compare to CVKD and RDHL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MDCX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CVKD (Cadrenal Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M) and RDHL (Redhill Biopharma Ltd.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $3.4M). Among the 5-stock peer group, MDCX leads on earnings multiple (N/A) while MDCX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MDCX?

Per MDCX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001997296), Medicus Pharma Ltd. generated $96.2M in revenue (+207.3% YoY), -$47.3M in net income, and -$22.8M in free cash flow against $10.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MDCX trading relative to its 50-day, 200-day, and 52-week technical levels?

MDCX last traded at $1.93 (+2.66% on volume of 31,237 shares), positioning the stock -71.70% below its 50-day simple moving average ($6.82) and -91.29% below its 200-day simple moving average ($22.17). Across its 52-week range of $1.82 to $127.50, MDCX sits at the 0.1% percentile with a 14-day RSI of 20.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.69 to $2.17).

Direct Sub-Reports: MDCX RQD Cockpit MDCX 12M Forecast MDCX Earnings & Move MDCX Dividends & DRIP MDCX Insiders & 13F MDCX Whale Options MDCX Profit Sankey MDCX News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

MDCX — Medicus Pharma Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Medicus Pharma Ltd. (MDCX) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.93 (+2.66% 1D, market capitalization $3.6M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Medicus Pharma Ltd. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry.. — for the specific products, customers, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Medicus Pharma Ltd. (MDCX) reported $96.2M in annual revenue (up from $31.3M in FY2024, +207.3% YoY) and -$47.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($13.2M revenue, -$5.3M net income) through FY2025, MDCX scaled operating cash flow to -$22.8M and free cash flow to -$22.8M, backed by $10.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.82 – $127.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply_chain field is "NONE" and the butterfly_links and proprietary_signals lists are empty. Upstream suppliers, downstream customers, and sector correlations cannot be mapped from the supplied data. For a prospective investor, the relevant second-order watch items within the supplied information are the reverse split's effect on share count and liquidity and the dependence of the oncology pipeline on partnerships and clinical progress, neither of which is quantified in the source data.

  • Key Question #1: Can MDCX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $96.2M and free cash flow of -$22.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MDCX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MDCX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Medicus Pharma Ltd. (MDCX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MDCX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MDCX Bull vs. Bear Conversation Board — What's Your Call at $1.93?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MDCX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MDCX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $2.18 (+16.0%)
📌 Pinned Debate

Regained Nasdaq minimum bid compliance after ten consecutive business days of $1-or-higher bids, with oncology pipeline milestones cite

Picked up a starter position in MDCX in my $100K Virtual Cash book at $1.88. Regained Nasdaq minimum bid compliance after ten consecutive business days of $1-or-higher bids, with oncology pipeline milestones cited as catalysts.. Trading inside a $1.82–$127.50 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@BreakoutHunter Agree on the RQD 34/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.88 and keeping dry powder in case we test $1.75.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $1.56 (-17.0%)
Spot @ $1.88

Reported operating losses of -$34.4M and negative free cash flow of -$22.8M in FY 2025 against zero revenue, with ROIC at -35% and Piot

Fading this rally in MDCX at $1.88. Reported operating losses of -$34.4M and negative free cash flow of -$22.8M in FY 2025 against zero revenue, with ROIC at -35% and Piotroski F-Score at 1 out of 9.. With a beta of 1.0 and the stock sitting at $1.88 (52-wk range $1.82–$127.50), the easy multiple expansion is already priced in.

LIVE TAPE